LANDOS BIOPHARMA INC
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It is engaged in the clinical development of compounds that target pathways at the interface of immunity and metabolism. Its lead candidate is NX-13, an oral, gut-selective NLRX1 agonist. It is developing NX-13 as a once-daily oral treatment for ulcerative colitis (UC) that targets the NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines in UC. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. In addition to NX-13, it has discovered several preclinical product candidates, such as LABP-73, LABP-66 and LABP-69. LABP-73, an oral, small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease.
Buy US stocks in Australia starting with LABP. Open an account and start investing today!
Ready to start your investing journey with Stake?Open an account
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in LABP
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in LABP
Buy LABP from US$3 brokerage
Invest in 6,000+ U.S. stocks and ETFs
Own a slice of LABP from only US$10 with fractional shares